Roche has announced the launch of its cobas Zika test to markets that accept the CE mark.

The cobas Zika test, which is intended for use in screening blood donations, is compatible with the cobas 6800/8800 systems.

The qualitative in vitro nucleic acid screening test is for the direct detection of Zika virus RNA in plasma specimens from donors of both whole blood and blood components, and other living donors. The test provides solutions for blood services to detect the Zika virus to ensure that infected blood units are not made available for transfusion.

Zika is linked to brain defects in foetuses and newborns and neurological complications in children and adults. The virus is mainly spread through the bite of infected mosquitos, but infected blood from an asymptomatic donor which is used in a transfusion could serve as an additional transmission route for the virus.

French authorities have recently reported three cases of Zika infection which appear to have been acquired locally, highlighting the ongoing need for blood banks to be prepared with solutions for tropical diseases.

Roche head of molecular diagnostics Mario Torres said: “Together with cobas CHIKV/DENV to screen for chikungunya and dengue viruses, the cobas Zika test provides a solution for preserving blood safety in regions with local outbreaks of these tropical diseases or from donors who may have been exposed while traveling to outbreak areas.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Launching the cobas Zika test in markets accepting the CE mark expands the emergency preparedness solution for our customers and helps minimize the risk of transmission through infected blood and plasma donations.”

The cobas 6800/88000 systems are fully automated and offer the fastest time to results, highest throughput and longest walk-away time available among automated molecular platforms, Roche said.

Not all of the assays available for the systems are available in every market worldwide.